Charles River Laboratories (CRL) Tops Q2 EPS by 10c; Bumps Outlook Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
Charles River Labs (CRL) PT Raised to $100 at Jefferies
August 4, 2016 10:50 AM EDTJefferies analyst raised his price target on Buy-rated Charles River Labs (NYSE: CRL) to $100.00 (from $94.00) following recent earnings.
commented, "CRL displayed continued strength across all segments. Integration of WIL is underway and should lead to margin leverage from the $17-20M cost synergies. CRL is the pre-clinical CRO "category killer" and continues to drive share gains and revenue growth through comprehensive offerings and a focus on high quality science with benefits to utilization, price, and margin."
The analyst had 4 Key Insights:
1) DSA Outperforms in 1st Quarter with WIL. DSA revenue grew... More
Charles River Labs (CRL) PT, Estimates Raised at Evercore ISI
August 3, 2016 11:08 AM EDTEvercore ISI analyst Ross Muken raised estimates and his price target on Charles River Labs (NYSE: CRL) to $91.50 (from $83.50) but maintained a Hold rating.
Muken commented, "Charles Rivers epic nine quarter run continued (core growth in HSD) as biopharma end market strength remains the main story. Strong demand across the... More
